Drug Trial Radar · NCT04896008
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
Last checked: Nov 20, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
173
Actual
Start
Dec 1, 2021
Primary completion
Jul 26, 2024
Study completion Feb 18, 2025
Sponsor
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAIndustry
- Sponsor type
- Industry
- First posted
- May 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension \[PAH\] therapy) versus placebo (plus maximum tolerated background PAH therapy) on time to first event of all cause death, lung transplantation, or PAH worsening-related hospitalization of ≥24 hours, in participants with World Health Organization (WHO) functional class (FC) III or FC IV PAH at high risk of mortality.
Conditions
- Pulmonary Arterial Hypertension
Interventions
SotaterceptDrug
SC injection
PlaceboOther
Placebo-matched SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Confirmed Morbidity or Mortality EventTime frame: Up to approximately 31 months
Locations
57 sites in 12 countries. Site status is shown where the registry gives one.
Arizona Pulmonary Specialists ( Site 1010)
Phoenix, Arizona
David Geffen School of Medicine at UCLA ( Site 1068)
Los Angeles, California
University of California Irvine ( Site 1086)
Orange, California
University of California San Diego Medical Center ( Site 1002)
San Diego, California
University of California San Francisco ( Site 1019)
San Francisco, California
University of Colorado Hospital ( Site 1013)
Aurora, Colorado
The George Washington University Medical Faculty Associates ( Site 1025)
Washington D.C., District of Columbia
Mayo Clinic Jacksonville - PPDS ( Site 1045)
Jacksonville, Florida
AdventHealth Medical Group Advanced Lung Disease ( Site 1058)
Orlando, Florida
Northside Hospital ( Site 1073)
Atlanta, Georgia
University Of Iowa Hospitals and Clinics ( Site 1050)
Iowa City, Iowa
University of Kansas Medical Center ( Site 1020)
Kansas City, Kansas
Tufts Medical Center - PPDS ( Site 1012)
Boston, Massachusetts
Brigham and Women's Hospital ( Site 1014)
Boston, Massachusetts
University of Michigan ( Site 1011)
Ann Arbor, Michigan
Washington University School of Medicine ( Site 1022)
St Louis, Missouri
University of Nebraska Medical Center ( Site 1053)
Omaha, Nebraska
University of New Mexico Health Sciences Center ( Site 1048)
Albuquerque, New Mexico
University of Rochester Medical Center - PPDS ( Site 1039)
Rochester, New York
Duke University Medical Center ( Site 1026)
Durham, North Carolina
University of Cincinnati Medical Center ( Site 1035)
Cincinnati, Ohio
The Cleveland Clinic Foundation. ( Site 1065)
Cleveland, Ohio
Medical University of South Carolina - PPDS ( Site 1003)
Charleston, South Carolina
Statcare Pulmonary Consultants - Knoxville ( Site 1031)
Knoxville, Tennessee
University Of Texas Southwestern Medical Center ( Site 1038)
Dallas, Texas
Medical College of Wisconsin - Froedtert Hospital ( Site 1051)
Milwaukee, Wisconsin
St Vincent's Hospital Sydney ( Site 1102)
Darlinghurst, New South Wales, Australia
John Hunter Hospital ( Site 1101)
New Lambton Heights, New South Wales, Australia
Hôpital Erasme ( Site 1402)
Anderlecht, Bruxelles-Capitale, Region de, Belgium
UZ Leuven Campus Gasthuisberg ( Site 1401)
Leuven, Vlaams-Brabant, Belgium
Peter Lougheed Centre ( Site 2102)
Calgary, Alberta, Canada
Jewish General Hospital ( Site 2103)
Montreal, Quebec, Canada
Hôpitaux Universitaires de Strasbourg ( Site 1307)
Strasbourg, Bas-Rhin, France
Centre Hospitalier Universitaire de Toulouse. ( Site 1315)
Toulouse, Haute-Garonne, France
CHU de Nancy - Hôpital de Brabois Adultes ( Site 1308)
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France
CHRU Lille ( Site 1306)
Lille, Nord, France
Hôpital Louis Pradel ( Site 1317)
Bron, Rhone, France
CHU Bicêtre ( Site 1304)
Le Kremlin-Bicêtre, Val-de-Marne, France
CHU de Poitiers ( Site 1316)
Poitiers, Vienne, France
Thoraxklinik-Heidelberg gGmbH ( Site 1509)
Heidelberg, Baden-Wurttemberg, Germany
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.